Is APOE ε4 associated with cognitive performance in early MS?
Open Access
- 1 May 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Neuroimmunology & Neuroinflammation
Abstract
Objective To assess the impact of APOE polymorphisms on cognitive performance in patients newly diagnosed with clinically isolated syndrome (CIS) or relapsing-remitting MS (RRMS). Methods This multicenter cohort study included 552 untreated patients recently diagnosed with CIS or RRMS according to the 2005 revised McDonald criteria. The single nucleotide polymorphisms rs429358 (ε4) and rs7412 (ε2) of the APOE haplotype were assessed by allelic discrimination assays. Cognitive performance was evaluated using the 3-second paced auditory serial addition test and the Multiple Sclerosis Inventory Cognition (MUSIC). Sum scores were calculated to approximate the overall cognitive performance and memory-centered cognitive functions. The impact of the APOE carrier status on cognitive performance was assessed using multiple linear regression models, also including demographic, clinical, MRI, and lifestyle factors. Results APOE ε4 homozygosity was associated with lower overall cognitive performance, whereas no relevant association was observed for APOE ε4 heterozygosity or APOE ε2 carrier status. Furthermore, higher disability levels, MRI lesion load, and depressive symptoms were associated with lower cognitive performance. Patients consuming alcohol had higher test scores than patients not consuming alcohol. Female sex, lower disability, and alcohol consumption were associated with better performance in the memory-centered subtests of MUSIC, whereas no relevant association was observed for APOE carrier status. Conclusion Along with parameters of a higher disease burden, APOE ε4 homozygosity was identified as a potential predictor of cognitive performance in this large cohort of patients with CIS and early RRMS.Keywords
This publication has 36 references indexed in Scilit:
- Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosisMultiple Sclerosis Journal, 2013
- Risk factors for and management of cognitive dysfunction in multiple sclerosisNature Reviews Neurology, 2011
- The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigueMultiple Sclerosis Journal, 2009
- Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophyNeurology, 2009
- Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MSMultiple Sclerosis Journal, 2009
- Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing–remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) studyMultiple Sclerosis Journal, 2009
- APOE ε4 allele is associated with cognitive impairment in patients with multiple sclerosisNeurology, 2008
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Annals of Neurology, 2005
- Ein neuropsychologisches Screening zur Erfassung kognitiver Störungen bei MS-Patienten - Das Multiple Sklerose Inventarium Cognition (MUSIC)psychoneuro, 2004
- Differential Effects of Apolipoproteins E3 and E4 on Neuronal Growth in VitroScience, 1994